



Figure 1




= SOLID SUPPORT

R = TERMINAL PROTECTING GROUP
FOR EXAMPLE:
DIMETHOXYSYTRITYL (DMT)

(1) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)
(2) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)



INVERTED DEOXYABASIC SUCCINATE
LINKAGE



GLYCERYL SUCCINATE LINKAGE

Figure 2




Figure 3





Figure 4




POSITIONS (NN) CAN COMprise ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES
(eg. THYMIDINE) OR UNIVERSAL BASES

B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONALLY PRESENT

L = GLYCERYL MOIETY THAT IS OPTIONAL PRESENT

E = GLYCERATE MOIETY; HERE IS OFIONATE PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

Figure 5



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro

italic lower case = 2'-deoxy-2'-fluoro

underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY

B = INVERTED DEOXYABASIC

L = GLYCERYL MOIETY OPTIONAL PRESENT

S = PHOSPHOROTHIOATE OR
PHOSPHORODITHIOATE

Inventor's Name: McSwiggen et al.

Title: RNA Interference Mediated Inhibition of Platelet-Derived Endothelial Cell.....

Docket No. MBHB03-332-B (400/126)

Sheet 6 of 11

Figure 6




Figure 7




Figure 8

Inventor's Name: McSwiggen et al.
 Title: RNA Interference Mediated Inhibition of Platelet-Derived Endothelial Cell.....
 Docket No. MBHB03-332-B (400/126)
 Sheet 8 of 11




Figure 9: Target site Selection using siRNA





Figure 10



R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl
B = Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).

Figure 11: Modification Strategy

